Paper Details

  1. Home
  2. Paper Details

The effect of six months of daily treatment with the beta-2 agonist oral pirbuterol on pulmonary hemodynamics in patients with chronic hypoxic cor pulmonale receiving long-term oxygen therapy.

Author: BiernackiW, FlenleyD C, MacNeeW, PrinceK, WhyteK

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This double-blind study in 11 patients with chronic obstructive pulmonary disease (COPD) evaluated the acute and long-term effects of the oral beta-2 agonist pirbuterol on pulmonary hemodynamics and ventricular ejection fractions. An acute dose of pirbuterol increased heart rate, cardiac output, and right ventricular ejection fraction without affecting mean pulmonary arterial pressure. Long-term treatment with pirbuterol did not significantly alter any of these variables. The study suggests that pirbuterol may be a safe and effective treatment option for COPD, with no evidence of long-term adverse cardiovascular effects.
Paper Details　
Original Abstract of the Article :
We studied the acute and long-term effect of the oral beta-2 agonist pirbuterol on pulmonary hemodynamics and right and left ventricular ejection fractions in 11 patients with stable hypoxic chronic bronchitis and emphysema who were maintained on long-term oxygen therapy. We have used a double-blind...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1164/ajrccm/139.2.492

データ提供：米国国立医学図書館（NLM）

Pirbuterol's Impact on Pulmonary Hemodynamics in Chronic Hypoxic Cor Pulmonale

The study delves into the vast and complex landscape of pulmonary hemodynamics, focusing on the effects of pirbuterol, a beta-2 agonist, on patients with chronic hypoxic cor pulmonale (CHCP). The researchers conducted a double-blind, randomized crossover trial involving 11 patients with stable CHCP who were receiving long-term oxygen therapy. They carefully monitored the patients' pulmonary hemodynamics, including heart rate, cardiac output, and right ventricular ejection fraction, over a 6-month period, comparing pirbuterol treatment to a placebo. The results demonstrated a significant short-term improvement in heart rate, cardiac output, and right ventricular ejection fraction following a single dose of pirbuterol. However, these improvements were not sustained over the long-term, suggesting that pirbuterol may not be a long-term solution for improving pulmonary hemodynamics in patients with CHCP.

Pirbuterol: A Transient Oasis in the Desert of CHCP

This study highlights the importance of considering both short-term and long-term effects of treatment interventions. While pirbuterol provides a temporary benefit, its impact on CHCP appears to be transient. This finding underscores the need for continued research to identify more effective and lasting treatment strategies for this challenging condition.

Managing CHCP: A Long-Term Strategy

Understanding the limitations of pirbuterol in the management of CHCP emphasizes the importance of a multi-faceted approach to patient care. This may include lifestyle modifications, oxygen therapy, and other therapeutic options, each tailored to individual needs and aimed at improving quality of life and overall health. Furthermore, continuous research into the underlying mechanisms of CHCP is essential for developing more effective and sustainable treatment strategies.

Dr. Camel's Conclusion

Like a mirage in the desert, pirbuterol's impact on CHCP appears to be fleeting. This study reminds us that managing chronic conditions often requires a journey across the vast terrain of medical innovation, seeking lasting solutions for a healthier future. It's not just about finding a quick fix but about navigating the path to a healthier and more sustainable state of well-being.

Date :
  1. Date Completed 1989-03-09
  2. Date Revised 2016-11-23
Further Info :

Pubmed ID

2563321

DOI: Digital Object Identifier

10.1164/ajrccm/139.2.492

Related Literature

Article Analysis
・Effects of pirbuterol acetate oral inhalation
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.